Research Letter

Venom of a hill viridicornis inhibitsinhibits growth of human breast tumor in micemice

A hill centipede Scolopendra viridicornis (Arthropoda, wells of each plate (lacking cells) were utilized for venom blank Chilopoda, ) found in north-east India (Indo- (n=2) and medium/tetrazolium reagent blank (n=6) Burma region) features extensively in tribal folk medicine. background determination. Venom concentrations tested were Dipping the insect in colorless local wine brewed from rice 1.75 µg and 5 µg in 250 µl of cell culture. Working venom containing about 30% alcohol leads to oozing of the venom solutions were prepared at 7 µg/ml and 20 µg/ml of PBS from the tips of the poison claws. Oral ingestion of the alcoholic without calcium and magnesium. These venom concentrations solution is a popular treatment for various diseases were selected based on the concentrations of snake venom proliferating among tribals who display symptoms like chronic disintegrin that were tested for cancer cell cytotoxicity.[1] headache, persistent uterine bleeding, chronic loss of appetite, Culture plates were incubated for 6 days. On day 7, 50 µl of blood in stool, blood and pus in urine, and white vaginal MTT working solution (1 mg/ml of PBS) was added to each discharge. This treatment is now popularly used in Manipur well. After 4 h incubation at 37°C, culture plates were for cancer patients as a last resort. Use of this venom in centrifuged at 2000 rpm for 5 min. Supernatant was removed traditional medicine and the reports of antitumor activity of from wells by slow aspiration through a blunt 18-gauze needle snake venom disintegrins[1] led us to examine similar activity leaving about 20-30 µl in each well. Then 150 µl of DMSO of the venom. Turbidimetric test of the venom using human (Sigma, St.Louis) was added to each well. After thorough thrombocytes showed positive disintegrin activity (unpublished mixing with a mechanical plate shaker, absorbance at 540 nm observation) and this further led us to examine anticancer was measured with a Multiskan MS microwell plate reader. properties of the venom. Since an antitumor agent may be Cell growth inhibition was expressed in terms of percentage cytotoxic[3] or noncytotoxic[7] in vitro MTT [3-(4,5­ of control absorbance (±1 SD% ) following subtraction of mean Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium Bromide] assay background absorbance. to detect cytotoxic antitumor property and in vivo test using For in vivo antitumor test in , approval of the tumor mouse model to detect noncytotoxic antitumor property University Ethics Committee was obtained and the guidelines were used. in accordance with CPCSEA were followed. Among the five The following cell lines were purchased from the National human cancer cell lines used here, breast tumor cell line HBL­ Centre for Cell Science, Pune University Campus, Pune: Hep 100 was tumorigenic in mouse.[6] Human breast tumor model 3B (ATCC NO. HB8064) – hepacellular carcinoma, HBL-100 in mouse established with HBL-100 was, therefore, used for (ICLC NO. HTL 00004)- breast myoepithelial tumor, IMR-32 in vivo test of the venom. The heterologous tumor mouse model (ATCC NO. CCL-127) – neuroblastoma, HEL 92.1.7 (ATCC NO. was established according to Price et al.[5] Mice (n=20) were TIB 180) – leukemia, ACHN (ATCC NO. CRL – 1611) – renal cell anaesthetized by ether (BDH, Mumbai) in a closed chamber. A adenocarcinoma. 1 cm longitudinal incision was made on the lateral side of the Inbred female Swiss albino virgin mice, 15 weeks old, second nipple from the rostral side where the mammary fat 25-30 g in weight were used. Due to the involvement of surgical pad beneath the skin was carefully exposed. HBL-100 cells (5 procedure in the experiment, the mice were kept in well x 105) suspended in 0.1 ml PBS (Glaxo, Mumbai) were injected maintained formalin fumigated cages and room. into the mammary fat pad. The wound was then sutured. Scolopendra viridicornis was collected from the hills. The Palpable tumor masses appeared on day 16 after injection with specimens were identified following the key to family tumor cells in 14 of the 20 mice and on day 30 in the remaining Scolopendridae. The venom was obtained by electrical 6 mice. stimulation of 2000 live as described for scorpion On the day palpable tumor mass appeared (zero week), milking.[2] mice were randomized into control and treatment groups (10 MTT assay, was used for in vitro cytotoxicity test and was each). Daily infiltrative injections into the established tumor performed as per the method of Alley et al.[3] Cells were masses were carried out with 5 µg (maximum dose of harvested from experimental-phase maintenance cultures. cytotoxicity test) of venom in 0.1 ml of 0.15 M NaCl over a Four hundred cells were counted by trypan blue exclusion and period of seven weeks. The control animals received dispensed within triplicate 96-well culture plates in 100 µl corresponding volume of venom carrier (NaCl solution). Tumor volumes for each venom concentration. The assay at each mass in each was a single lump that remained concentration was repeated twice. inseparable into composites throughout the experimental

Following a 24 h incubation at 37°C, 5% CO2, 100% RH period. Diameters of the tumor masses (sub-cutaneous) were

(Shellab 2123 CO2 incubator) 100 ml each of culture medium, measured weekly beginning from zero week with a caliper and venom solution and venom carrier (PBS) were dispensed tumor sizes were calculated from the formula: volume (mm3) (carrier control group n=6, each drug group n=3). Peripheral = (width) 2 x length x 0.5. Intensity of inhibition = (Mean control

Indian J Pharmacol | August 2006 | Vol 38 | Issue 4 | 291-292 291 Research Letter volume – mean treatment volume) X 100 ÷ Mean control Figure 1. Effect of S. viridicornis on proliferation of five human cancer volume. Significance of difference in tumor size between cell lines in vitro. Each point expresses mean from six replicate wells treatment and control was tested by student t-test. P<0.05 and error bar represents SD. was considered significant. HBL-100 HEL 92.1.7 105 Hep 36 IMR 32 The venom at 7 µg/ml and 20 µg/ml did not cause 104 103 ACHN significant reduction in light absorbance of MTT reaction 102 102 mixtures of all the cancer cell lines tested indicating that the 101 100 100 100 venom did not specifically kill cancer cells leaving the normal 99 99 98 98 cells unharmed. [Figure 1] 97 97 96 96 Daily injection of venom 5 µg into the tumors over a seven 95 95 95 94 94 week period showed that mean growth of tumors was 93 93 92 substantially lower than that of control. [P<0.01; Table 1] Mean 91 HBL-100 HEL 92.1.7 90 growth of control tumors (n=10) was 37 times the initial 89 Hep 36 IMR 32 88 volume, compared to venom treated tumors (n=10) which was 87 ACHN 86 only seven times the initial volume. Intensity of tumor growth 85 inhibition by the venom was 81.61%. During venom treatment, 00 1 2 3 4 5 6 7 8 9 11001 112131411551 61718192020 the appearance of tumor area, bleeding or oozing of body fluid V Venom concentrationt ti (µg/ml)( i from the venom injection site, food intake were monitored daily, and body weights were measured weekly. No abnormality was observed. Tumorigenicity of HBL-100 cell line in mouse has already [6] MTT assay originally developed for cell viability testing is been demonstrated. Cytotoxic antitumor agents selectively now widely used in cancer cell cytotoxicity testing.[3] Negative kill cancer cells through various mechanisms and exhibit results in MTT assay of S. viridicornis venom against five human positive results in both the in vitro and the in vivo antitumor [4] cancer cell lines show that the venom is not cytotoxic to the tests. On the other hand noncytotoxic antitumor agents inhibit cancer cell lines at the doses tested. Although a cancer cell tumor progression through suppression of processes cytotoxic agent may not be effective against certain cancer associated with tumorigenesis displaying positive results only [7] cell lines considering the number and diversity of the cell lines in the in vivo antitumor test. Considering these present and tested, the venom is unlikely to be cytotoxic to other cancer earlier observations, it is evincing that S. viridicornis venom cell lines. has noncytotoxic antitumor property although further test Inspite of noncytotoxicity the venom substantially inhibited should corroborate it. cancer progression in an in vivo model indicating that it Acknowledgment interacts with cancer progression factors rather than acting We are grateful to the Department of Biotechnology, Government of India for finan­ directly on cancer cells. Because of limited supply of venom cial support for this work the test was conducted using only one tumor model albeit an antitumor testing protocol used by others as well.[4] As in the T. Bhagirath, B. Chingtham, Y. Mohen* case of present study, use of tumor models established in Department of Life Sciences, Manipur University, Canchipur, immuno-competent mice for antitumor test has been Imphal – 795003. *Department of Pathology, Regional reported.[4] Institute of Medical Sciences, Lamphel, Imphal – 795001. E-mail: [email protected]

Table 1 References 1. Zhou Q, Sherwin RP, Parrish C, Richters V, Groshen SG, Tsao-Wei D, et al. Effect of S. viridicornis venom on the proliferation of HBL-100 Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix, inhibits breast human breast cancer cells in mouse mammary gland. cancer progression. Breast Cancer Res Treat 2000;61:249-60. 2. Tato P, Gavilanes M, Munoj L, Fletcher M, Molinary JL. In: Toxins – Animal, 3 Week Tumor volume (mm ) plant and microbial.Rosenberg P, editor. Oxford: Pergamon Press: 1978. 3. Alley MC, Scudiro DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Control Venom treated Feasibility of drug screening with panels of human cell lines using a microcul­ 0 10.9 ± 0.04 9.6 0 ± 0.03 ture tetrazolium assay. Can Res 1988;48:589-601. 4. Rajkapoor B, Jayakar B, Murugesh N. Anti-tumor activity of Indigofera 1 14.7 ± 0.08 10.6 ± 0.04* aspalathoides on Ehrlich ascites carcinoma in mice. Indian J Pharmacol 2 46.3 ± 0.05 12.4 ± 0.03* 2004;36:38-40. 3 69.3 ± 0.05 17.3 ± 0.06* 5. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of 4 101.2 ± 0.07 23.1 ± 0.05* human breast carcinoma cell lines in nude mice. Can Res 1990;50:717-21. 5 162.4 ± 0.12 34.0 ± 0.07* 6. Krief P, Saint-Ruf C, Bracke M, Boucheix C, Billard C, Billard M, et al. Acquisi­ 6 258.3 ± 0.17 42.2 ± 0.04* tion of tumorigenic potential in the human myoepithelial HBL 100 cell line is 7 404.3 ± 0.22 59.2 ± 0.06* associated with decreased expression of HLA class I, class II and integrin beta 3 and increased expression of C-myc. Int J Cancer 1989;43:658-64. 8 412.3 ± 0.18 75.8 ± 0.05* 7. O’Reilly MS, Homgren L, Shing Y, Chen C, Rosental RA, Cao Y, et al. Intensity of tumor growth inhibition = 81.61%. Values are mean+SEM. n=10 in Angiostatin: A circulating endothelial cell inhibitor that suppresses angiogen­ each group. *P<0.01 when compared to control. esis and tumor growth. In: Molecular Genetics of Cancer. New York: CSHL Press; 1994.

292 Indian J Pharmacol | August 2006 | Vol 38 | Issue 4 | 291-292